search
Back to results

Real-time Monitoring of Kidney Grafts on Hypothermic Machine Perfusion (REMO-HYMAP)

Primary Purpose

Transplant;Failure,Kidney

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Monitoring biochemical concentrations during cold machine perfusion
Sponsored by
Accunea Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Transplant;Failure,Kidney focused on measuring creatinine, microdialysis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All organs to be used in the study must be intended for transplantation and not already rejected/discarded.
  • All organs must be sourced from deceased donors through NHSBT in the normal course of clinical activity.
  • Kidneys must come from marginal or 'imperfect' donors according to current clinical criteria. This typically indicates an age of 60 and over, or 50 and over with one or more premorbid conditions, including renal impairment, cerebrovascular disease, and hypertension.

Exclusion Criteria:

  • Organs from living donors are excluded.
  • Organs from young healthy donors are excluded.
  • Organs will be excluded if on the assessment of the clinical team they are not suitable for hypothermic machine perfusion. This indicates organs that have arrived with visible defects, or fall well outside the team's standard criteria for clinical acceptability (excessive time in transit, excessive warm ischaemia time, excessive cold ischaemia time, very poor pre-morbid donor condition).

Sites / Locations

  • Hammersmith HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Marginal Kidneys

Arm Description

Transplant patients receiving kidneys from deceased marginal donors: aged >= 60, or >= 50 with comorbid renal impairment, hypertension, or cerebrovascular disease. Following consent, kidneys will be cold perfused with preserving solution for 2-4 hours as per standard of care at the study centre. During this period, the kidneys will be monitored for creatinine, glucose, and lactate concentrations using three microdialysis probes placed into the tissue, the vein, and the ureter. Data will be blinded to clinicians. The probes will be removed at the end of the perfusion period and the organs will be transplanted or discarded according to clinical protocol. If transplanted, the study will monitor the patient's recovery for the first 30 days.

Outcomes

Primary Outcome Measures

Post-operative recovery of kidney function
Magnitude of change in patient baseline serum creatinine concentration pre- and post-operatively at 30 days (in umol/L)

Secondary Outcome Measures

Reintervention rate
Any need to return the patient to theatre or perform additional procedures following the transplant
Primary non-function
Number of participants with no change in serum creatinine concentration from baseline despite transplantation
Delayed graft function
Number of days with inadequate graft function following surgery (low urine output, static serum creatinine concentration)
Acute rejection
Number of patients experiencing immunological rejection of the organ
Post-operative complications
Rates of the most common complications including arterial, venous, or parenchymal thrombosis, ureteric leak or stenosis

Full Information

First Posted
November 2, 2020
Last Updated
May 27, 2022
Sponsor
Accunea Ltd.
Collaborators
Imperial College Healthcare NHS Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT04619732
Brief Title
Real-time Monitoring of Kidney Grafts on Hypothermic Machine Perfusion
Acronym
REMO-HYMAP
Official Title
A Clinical Pilot Study Investigating the Real-time Dynamics of Glucose, Lactate and Creatinine Concentrations in Marginal Donor Kidneys Undergoing Hypothermic Machine Perfusion
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2021 (Actual)
Primary Completion Date
April 30, 2023 (Anticipated)
Study Completion Date
April 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Accunea Ltd.
Collaborators
Imperial College Healthcare NHS Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A significant number of deceased donor kidneys donated for transplantation are not used and are thrown away due to lack of ways of checking their condition and function before the operation. This significantly reduces the number of potentially life saving transplants. The researchers wish to run a small pilot study to see if it is possible to improve the way transplant kidneys are assessed before transplantation by measuring how well they filter the blood, and how good their metabolism is. The researchers believe this new method will help transplant surgeons make better decisions about which kidneys to use. This pilot study will look at 10 kidneys obtained from older deceased donors. These kidneys are most at risk of being thrown away because of the condition of the donor they came from. At the hospital, these kidneys are usually put onto a machine which pumps cold preservation solution through them for a couple of hours. This time lets the transplant surgeons see how well or poorly the kidney responds to the flowing fluid. In this study the research team will do exactly the same, but also insert a small probe less than a millimetre in diameter into the kidney and the vein (draining blood pipe) and urine output to monitor a number of chemicals made by the kidney. The researchers believe that the changing levels of these chemicals will give the surgeons much more information than they have now. This probe is removed when the kidney is transplanted. Combining these levels with news of how well the patients recover after surgery will allow the research team to design a much larger study to get the right level of information to change the way surgeons choose kidneys and help more transplants happen in the future.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transplant;Failure,Kidney
Keywords
creatinine, microdialysis

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Marginal Kidneys
Arm Type
Experimental
Arm Description
Transplant patients receiving kidneys from deceased marginal donors: aged >= 60, or >= 50 with comorbid renal impairment, hypertension, or cerebrovascular disease. Following consent, kidneys will be cold perfused with preserving solution for 2-4 hours as per standard of care at the study centre. During this period, the kidneys will be monitored for creatinine, glucose, and lactate concentrations using three microdialysis probes placed into the tissue, the vein, and the ureter. Data will be blinded to clinicians. The probes will be removed at the end of the perfusion period and the organs will be transplanted or discarded according to clinical protocol. If transplanted, the study will monitor the patient's recovery for the first 30 days.
Intervention Type
Diagnostic Test
Intervention Name(s)
Monitoring biochemical concentrations during cold machine perfusion
Intervention Description
Three microdialysis probes will be introduced into the kidney tissues, the vein and ureter in order to measure creatinine, glucose and lactate while the organ is undergoing cold perfusion prior to transplantation.
Primary Outcome Measure Information:
Title
Post-operative recovery of kidney function
Description
Magnitude of change in patient baseline serum creatinine concentration pre- and post-operatively at 30 days (in umol/L)
Time Frame
30 days post-operatively
Secondary Outcome Measure Information:
Title
Reintervention rate
Description
Any need to return the patient to theatre or perform additional procedures following the transplant
Time Frame
30 days post-operatively
Title
Primary non-function
Description
Number of participants with no change in serum creatinine concentration from baseline despite transplantation
Time Frame
30 days post-operatively
Title
Delayed graft function
Description
Number of days with inadequate graft function following surgery (low urine output, static serum creatinine concentration)
Time Frame
30 days post-operatively
Title
Acute rejection
Description
Number of patients experiencing immunological rejection of the organ
Time Frame
30 days post-operatively
Title
Post-operative complications
Description
Rates of the most common complications including arterial, venous, or parenchymal thrombosis, ureteric leak or stenosis
Time Frame
30 days post-operatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All organs to be used in the study must be intended for transplantation and not already rejected/discarded. All organs must be sourced from deceased donors through NHSBT in the normal course of clinical activity. Kidneys must come from marginal or 'imperfect' donors according to current clinical criteria. This typically indicates an age of 60 and over, or 50 and over with one or more premorbid conditions, including renal impairment, cerebrovascular disease, and hypertension. Exclusion Criteria: Organs from living donors are excluded. Organs from young healthy donors are excluded. Organs will be excluded if on the assessment of the clinical team they are not suitable for hypothermic machine perfusion. This indicates organs that have arrived with visible defects, or fall well outside the team's standard criteria for clinical acceptability (excessive time in transit, excessive warm ischaemia time, excessive cold ischaemia time, very poor pre-morbid donor condition).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robert M Learney, MBBS PhD
Phone
02088741839
Email
robertlearney@accunea.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vassilios Papalois, MD PhD
Organizational Affiliation
Imperial College Healthcare NHS Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hammersmith Hospital
City
London
ZIP/Postal Code
W12 0HS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Becky Ward
Phone
02075949459
Email
becky.ward@imperial.ac.uk
First Name & Middle Initial & Last Name & Degree
Vassilios E Papalois, MD PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plan to share non-anonymised patient data with other researchers.

Learn more about this trial

Real-time Monitoring of Kidney Grafts on Hypothermic Machine Perfusion

We'll reach out to this number within 24 hrs